Cargando…

ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production

INTRODUCTION: EGFR mutations in non-small cell lung cancer (NSCLC) are associated with a poor response to immune checkpoint inhibitors (ICIs), and only 20% of NSCLC patients harboring EGFR mutations benefit from immunotherapy. Novel biomarkers or therapeutics are needed to predict NSCLC prognosis an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Dantong, Qian, Haili, Wang, Jinsong, Xie, Tongji, Teng, Fei, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558404/
https://www.ncbi.nlm.nih.gov/pubmed/36229854
http://dx.doi.org/10.1186/s12964-022-00958-5